不同的基因组集群对先进胆道癌症的反应产生影响,这些患者接受了西斯普拉丁加盖米奇塔加杜尔瓦卢马布治疗
Margherita Rimini1,2, Eleonora Loi3, Mario Domenico Rizzato4,5
1IRCCS San Raffaele Scientific Institute Hospital, Vita-Salute San Raffaele University, Milan, Italy. margherita.rimini@gmail.com.
Targeted oncology
|February 12, 2024
概括
这项研究将胆管癌患者分为三个基因组集群. 集群2对化疗和杜尔瓦卢马布的整体反应率较高,而集群3没有反应.
科学领域:
- 对癌症患者的基因组分析.
- 在瘤学中进行分子分析.
- 在胆管癌中发现生物标志物
背景情况:
- 西斯丁,格姆西塔宾和杜尔瓦卢马布组合是先进胆管癌的标准一线治疗方法.
- 基于分子形状的患者分层可以优化治疗策略.
- 了解基因组变化对于向治疗至关重要.
研究的目的:
- 根据突变概况将胆管癌患者分为不同的组.
- 将这些分子与临床结果相关联,特别是总体反应率.
- 为了确定胆管癌中治疗反应的潜在生物标志物.
主要方法:
- 选择了51名胆管癌患者,接受化疗和杜尔瓦卢马布治疗.
- 使用下一代测序 (FoundationOne基因面板) 进行瘤突变分析.
- 进行基于突变的聚类和生存分析,以确定患者群体和结果.
主要成果:
- 根据基因组变化确定了三个不同的患者群.
- 集群1:主要是染色体修饰路径突变 (100%改变).
- 集群2:对DNA损伤控制,染色体修饰,RTK/RAS,细胞周期亡,TP53和PI3K通路的改变. 显示了50%的整体响应率 (12/24).
- 集群3:主要是RTK/RAS和细胞周期亡途径的改变. 显示了0%的整体响应率 (0/10).
- 在集群中总体反应率的统计学上显著差异 (p = 0.0188).
结论:
- 根据不同的分子和基因组变化对患者进行分组,揭示了不同的治疗反应.
- 集群2的患者对化疗和杜尔瓦卢马布的整体反应率较高.
- 第三组患者没有表现出客观反应,这表明了潜在的耐药性机制.
- 为了证实这些发现,需要在更大的队列中进一步验证.
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K